Biomea Fusion, Inc. General and Administrative Expense
Biomea Fusion, Inc. (BMEA) reported General and Administrative Expense of $3.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-08-05
- Biomea Fusion, Inc. general and administrative expense for the quarter ending 2026-06-30 was $3.62M, a 23.06% decline year-over-year.
- Biomea Fusion, Inc. general and administrative expense for the quarter ending 2026-03-31 was $3.65M, a 46.38% decline year-over-year.
- Biomea Fusion, Inc. general and administrative expense for the quarter ending 2025-12-31 was $3.60M, a 25.44% decline year-over-year.
- Biomea Fusion, Inc. general and administrative expense for the quarter ending 2025-09-30 was $4.20M, a 38.20% decline year-over-year.
- Biomea Fusion, Inc. general and administrative expense for fiscal 2025 was $19.33M, a 25.62% decline from fiscal 2024.
- Biomea Fusion, Inc. general and administrative expense for fiscal 2024 was $25.98M, a 10.16% increase from fiscal 2023.
- Biomea Fusion, Inc. general and administrative expense for fiscal 2023 was $23.59M, a 12.75% increase from fiscal 2022.
- Biomea Fusion, Inc. general and administrative expense for fiscal 2022 was $20.92M, a 53.03% increase from fiscal 2021.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 6 month | General and Administrative Expense 9 month | General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.62M 10-Q · filed 2026-08-05 | $7.28M 10-Q · filed 2026-08-05 | $10.88M derived: sum of 3 quarters · filed 2026-08-05 | $15.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.65M 10-Q · filed 2026-05-11 | $7.26M derived: sum of 2 quarters · filed 2026-05-11 | $11.46M derived: sum of 3 quarters · filed 2026-05-11 | $16.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $7.80M derived: sum of 2 quarters · filed 2026-03-24 | $12.51M derived: sum of 3 quarters · filed 2026-08-05 | $19.33M 10-K · filed 2026-03-24 |
| 2025-09-30 | $4.20M 10-Q · filed 2025-11-04 | $8.91M derived: sum of 2 quarters · filed 2026-08-05 | $15.72M 10-Q · filed 2025-11-04 | $20.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.71M 10-Q · filed 2026-08-05 | $11.53M 10-Q · filed 2026-08-05 | $16.36M derived: sum of 3 quarters · filed 2026-08-05 | $23.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $6.82M 10-Q · filed 2026-05-11 | $11.65M derived: sum of 2 quarters · filed 2026-05-11 | $18.44M derived: sum of 3 quarters · filed 2026-05-11 | $25.52M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $4.83M 10-K · filed 2025-03-31 | $11.63M derived: sum of 2 quarters · filed 2025-11-04 | $18.70M derived: sum of 3 quarters · filed 2025-11-04 | $25.98M 10-K · filed 2026-03-24 |
| 2024-09-30 | $6.79M 10-Q · filed 2025-11-04 | $13.87M derived: sum of 2 quarters · filed 2025-11-04 | $21.15M 10-Q · filed 2025-11-04 | $27.61M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $7.07M 10-Q · filed 2025-08-05 | $14.36M 10-Q · filed 2025-08-05 | $20.82M derived: sum of 3 quarters · filed 2025-08-05 | $26.59M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $7.28M 10-Q · filed 2025-05-05 | $13.74M derived: sum of 2 quarters · filed 2025-05-05 | $19.52M derived: sum of 3 quarters · filed 2025-05-05 | $25.24M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $6.46M 10-K · filed 2025-03-31 | $12.23M derived: sum of 2 quarters · filed 2025-03-31 | $17.95M derived: sum of 3 quarters · filed 2025-03-31 | $23.59M 10-K · filed 2026-03-24 |
| 2023-09-30 | $5.77M 10-K · filed 2025-03-31 | $11.49M derived: sum of 2 quarters · filed 2025-03-31 | $17.13M 10-Q · filed 2024-10-29 | $22.86M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | $5.72M 10-K · filed 2025-03-31 | $11.36M 10-Q · filed 2024-07-31 | $17.09M derived: sum of 3 quarters · filed 2025-03-31 | $22.33M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | $5.64M 10-K · filed 2025-03-31 | $11.37M derived: sum of 2 quarters · filed 2025-03-31 | $16.61M derived: sum of 3 quarters · filed 2025-03-31 | $21.51M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | $5.74M 10-K · filed 2024-03-28 | $10.98M derived: sum of 2 quarters · filed 2024-03-28 | $15.87M derived: sum of 3 quarters · filed 2024-03-28 | $20.92M 10-K · filed 2025-03-31 |
| 2022-09-30 | $5.24M 10-K · filed 2024-03-28 | $10.13M derived: sum of 2 quarters · filed 2024-03-28 | $15.18M 10-Q · filed 2023-10-30 | $18.83M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | $4.89M 10-K · filed 2024-03-28 | $9.94M 10-Q · filed 2023-07-31 | $13.59M derived: sum of 3 quarters · filed 2024-03-28 | $18.34M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | $5.05M 10-K · filed 2024-03-28 | $8.70M derived: sum of 2 quarters · filed 2024-03-28 | $13.45M derived: sum of 3 quarters · filed 2024-03-28 | $16.66M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | $3.65M 10-K · filed 2023-03-28 | $8.40M derived: sum of 2 quarters · filed 2023-03-28 | $11.61M derived: sum of 3 quarters · filed 2023-03-28 | $13.67M 10-K · filed 2024-03-28 |
| 2021-09-30 | $4.75M 10-K · filed 2023-03-28 | $7.96M derived: sum of 2 quarters · filed 2023-03-28 | $10.02M 10-Q · filed 2022-11-07 | $11.19M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $3.21M 10-K · filed 2023-03-28 | $5.27M 10-Q · filed 2022-08-01 | $6.44M derived: sum of 3 quarters · filed 2023-03-28 | $6.78M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $2.06M 10-K · filed 2023-03-28 | $3.23M derived: sum of 2 quarters · filed 2023-03-28 | $3.57M derived: sum of 3 quarters · filed 2023-03-28 | $3.65M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $1.17M 10-K · filed 2022-02-28 | $1.51M derived: sum of 2 quarters · filed 2022-02-28 | $1.59M derived: sum of 3 quarters · filed 2022-02-28 | $1.66M 10-K · filed 2023-03-28 |
| 2020-09-30 | $346.00K 10-K · filed 2022-02-28 | $425.00K derived: sum of 2 quarters · filed 2022-02-28 | $489.00K 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $79.00K 10-K · filed 2022-02-28 | $143.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $64.00K 10-K · filed 2022-02-28 | |||
| 2019-12-31 | $103.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |